122 related articles for article (PubMed ID: 38723388)
21. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
22. The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Kelsey JE; Neville C
Psychopharmacology (Berl); 2014 Jun; 231(12):2405-15. PubMed ID: 24402134
[TBL] [Abstract][Full Text] [Related]
23. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
24. Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Rentsch P; Stayte S; Morris GP; Vissel B
BMC Neurosci; 2019 Feb; 20(1):5. PubMed ID: 30760214
[TBL] [Abstract][Full Text] [Related]
25. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
26. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
[TBL] [Abstract][Full Text] [Related]
27. Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Gil SJ; Park CH; Lee JE; Minn YK; Koh HC
Brain Res Bull; 2011 Feb; 84(2):151-6. PubMed ID: 21163338
[TBL] [Abstract][Full Text] [Related]
28. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
[TBL] [Abstract][Full Text] [Related]
29. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
30. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
31. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
32. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
33. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
34. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
35. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
36. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Lindenbach D; Conti MM; Ostock CY; Dupre KB; Bishop C
Neuroscience; 2015 Dec; 310():12-26. PubMed ID: 26363150
[TBL] [Abstract][Full Text] [Related]
37. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
38. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Nascimento GC; Bariotto-Dos-Santos K; Leite-Panissi CRA; Del-Bel EA; Bortolanza M
Neurotox Res; 2018 Nov; 34(4):799-807. PubMed ID: 29611150
[TBL] [Abstract][Full Text] [Related]
39. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Jeon MY; Lee WY; Kang HY; Chung EJ
Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
[TBL] [Abstract][Full Text] [Related]
40. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
